![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Atazanavir plus Cobicistat versus Atazanavir plus Ritonavir, Both in Combination with Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial
|
|
|
Reported by Jules Levin
EACS 2015 Oct 21-24 Barcelona, Spain
Graeme Moyle,1 Juan Berenguer,2 Edwin DeJesus,3 Joel Gallant,4 Peter Shalit,5 Joel Myers,6 Huyen Cao,7 Lisa Rosenblatt,6 Lingfeng Yang,8 Javier Szwarcberg7
1Chelsea and Westminster Hospital, London, UK; 2Hospital General Universitario Gregorio Marañón, Madrid, Spain; 3Orlando Immunology Center, Orlando, FL, USA; 4Southwest CARE Center, Santa Fe, NM, USA; 5Tribal Med, Seattle, WA, USA; 6Bristol Myers Squibb, Plainsboro, NJ, USA; 7Gilead Sciences, Inc., Foster City, CA, USA; 8Bristol Myers Squibb, Hopewell, NJ, USA
![EACS1.gif](../images/110515/110515-13/EACS1.gif)
![EACS2.gif](../images/110515/110515-13/EACS2.gif)
![EACS3.gif](../images/110515/110515-13/EACS3.gif)
![EACS4.gif](../images/110515/110515-13/EACS4.gif)
![EACS5.gif](../images/110515/110515-13/EACS5.gif)
![EACS6.gif](../images/110515/110515-13/EACS6.gif)
![EACS7.gif](../images/110515/110515-13/EACS7.gif)
![EACS8.gif](../images/110515/110515-13/EACS8.gif)
![EACS9.gif](../images/110515/110515-13/EACS9.gif)
![EACS10.gif](../images/110515/110515-13/EACS10.gif)
![EACS11.gif](../images/110515/110515-13/EACS11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|